Back to Search
JOSHUA BONI, MD
MD
Orthopaedic Surgery Physician
NPI: 1700240553IndividualAccepts Medicare
Specialties, Licenses & Credentials
Orthopaedic Surgery PhysicianPrimary
Orthopaedic Surgery
Code: 207X00000X
35.143412(OH)
CMS Specialties
PrimaryORTHOPEDIC SURGERY
Education
MEHARRY MEDICAL COLLEGE SCHOOL OF MEDICINE
Class of 2016
Research & Publications (18)
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
PMID 19415181·Invest New Drugs·2010
3-trial
Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
PMID 19526589·Cancer·2009
3-trial
Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus.
PMID 19015855·Cancer Chemother Pharmacol·2009
3-trial
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
PMID 18765554·Clin Cancer Res·2008
3-trial
Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus.
PMID 18458675·Br J Cancer·2008
8-other
Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications.
PMID 17913896·J Clin Pharmacol·2007
3-trial
Is bicarbonate buffer suitable as a dissolution medium?
PMID 17910812·J Pharm Pharmacol·2007
4-observational
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
PMID 17761980·J Clin Oncol·2007
3-trial
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
PMID 16710023·J Clin Oncol·2006
3-trial
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
PMID 17020981·Clin Cancer Res·2006
3-trial
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
PMID 15998902·J Clin Oncol·2005
3-trial
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
PMID 15955899·J Clin Oncol·2005
3-trial
Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer.
PMID 15637533·Clin Pharmacol Ther·2005
3-trial
Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis.
PMID 15176649·Int J Clin Pharmacol Ther·2004
3-trial
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.
PMID 15136596·J Clin Oncol·2004
3-trial
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
PMID 14990647·J Clin Oncol·2004
3-trial
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
PMID 12796032·Ann Oncol·2003
3-trial
Chiral bioequivalence: effect of absorption rate on racemic etodolac.
PMID 11192477·Clin Pharmacokinet·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4100 JOHNSON RD STE 103
STEUBENVILLE, OH 43952 - Phone
- (740) 283-2062
Quick Facts
- NPI
- 1700240553
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 10
- Publications
- 18
Are you this provider?
Claim Your Profile